Articles On Noxopharm (ASX:NOX)

ShareCafeAustralia…1 hour in… ASX200 up 3 ASX200 up 3 points to 7182.   A2Milk (-0.5%); said it is aware of media reporting concerning a potential class action against them that is apparently being investigated by Slater & Gordon Lawye...

Wall Street higher as Biden proposed US$6 trillion budget All major indices rose on Friday, as US President Biden proposed a US$6 trillion budget spending for 2022, the highest US federal spend since WW2. The Dow Jones rose by 0.19%, S&...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

ShareCafeNoxopharm (ASX: NOX) – Webinar Presentation Presenter – Graham Kelly – CEO & MD – Noxopharm is a clinical stage drug development company. Noxopharm (ASX: NOX) – Webinar PresentationCompany News

ShareCafeHidden Gems Webinar Recap – LAU, NOX, TZL, ANP, VMS Catch up on the full webinar with presentations from  Antisense Therapeutics (ASX: ANP), Lindsay Australia (ASX: LAU), Noxopharm (ASX: NOX), Venture Minerals (ASX: VMS) & TZ...

In Part 1 of the study, an 1800 milligram dose of Veyonda® was determined to be well tolerated in patients with compromised lung function.

Summary The WCN share price has closed up by 17.6%, as the company announced assay results. QuickFee has seen a remarkable increase in lending activity in Australia. The DRE share price has risen by 8.7% to AU$0.025 in today’s session...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

The ASX 200 has rebounded from yesterday’s loss though the technology sector has weighed on the market for two consecutive weeks. The index closed 0.20 per cent higher, and is also up by 0.70 per cent for the week. IT slumped by another 2.5...

Noxopharm Ltd (ASX: NOX) shares are having a bumper end to the week after the company released a market update this morning. At the time of writing, the Noxopharm share price is storming 16.49% higher to 56.5 cents. In earlier trade, the c...

CEP-2 will build on the encouraging outcomes of the CEP-1 pilot study where the chemo-enhancing effect of Veyonda was used to lower dosages of chemotherapy in patients with advanced solid cancers.

Dow Jones and iron ore reset records The Dow Jones index rose again overnight by 0.93%, resetting the record highs it set the previous day. Other major US indices also rose, after jobless claims in the US came in less than expected. S&P...

The aim of the CEP-1 study is to show that Veyonda boosts the effectiveness of conventional chemotherapy to allow the use of lower, safer dosages of chemotherapy.

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

The data supports the international patent application lodged on 30 March 2021, making the provisional patent a potentially very valuable commercial asset.

The data supports the international patent application lodged on 30 March 2021, making the provisional patent a potentially very valuable commercial asset.

Noxopharm (ASX:NOX) has provided interim data from its NOXCOVID trial that is assessing the company's Veyonda in a cohort of 18 patients with moderately severe COVID- 19 disease.

The Noxopharm Ltd (ASX: NOX) share price has started the week on a positive note. At the time of writing, the clinical-stage drug development company’s shares are up 6% to 67 cents. Why is the Noxopharm share price charging higher? Investo...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced the lodgement of an international patent application aimed at protecting the use of Veyonda (idronoxil) in blocking the development of septic shock...

Peter Switzer speaks to Graham Kelly, the founder, CEO and managing director of Noxopharm (NOX).

A phase 1b clinical trial testing the safety and efficacy of Noxopharm (ASX:NOX)‘s Veyonda suppository when combined with Bristol Myer Squibb’s immunotherapy drug Opdivo (nivolumab) has received ethics approval. The IONIC-1 trial will immed...

ShareCafeAustralia…One Hour In…ASX200 down 69 points ASX200 down 69 points (1%) to 6676.   Afterpay (-2.8%) / Splitit (-3.2%) / Zip Co (-3.3%); press speculation  that the “RBA will move on the BNPL later sector to force industry players t...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Despite the healthcare leading the gains in the S&P/ASX 200 Index (ASX: XJO) yesterday, there are some healthcare shares that have been out-of-form over the last month. It can sometimes be useful to take a look at which shares are buck...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that its lead investigational candidate Veyonda has been approved to move into its second and final stage of the NOXCOVID-1 clinical trial.

The Noxopharm Ltd (ASX: NOX) share price is raced higher on the open this morning. However, the Noxopharm share price has since settled down. The movement comes as a result of the clinical drug developer provided an update on its NOXCOVID...

08 Mar 2021 - Drug development company Noxopharm (ASX:NOX) reports Veyonda has been approved to move into its second and final stage of the NOXCOVID-1 clinical trial.

ShareCafeAustralia…One Hour In…ASX200 up 49 points ASX200 up 49 points (0.7%) to 6838.   Don’t forget the Reserve Bank interest rate decision at 2.30pm.     No change is expected by just about all economists………….   Aristocrat (+0.8%); US F...

A trial of Noxopharm's (ASX: NOX) prostate cancer treatment has delivered a "high response" in men with end-stage cancer, sending the company's stocks up this morning. According to NOX, a trial of the company's LuPIN drug combination has...

ShareCafeNoxopharm Study Finds its Drug Improves Prostate Cancer Survival Rates Noxopharm (ASX:NOX) announced this week independent drug trial results that significantly extended the life of men with prostrate cancer. “Today’s clinical...

At time of writing, the share price of Noxopharm Ltd [ASX:NOX] is up more than 8%, trading at 74 cents. We look at the latest announcement out of the company and the outlook for the NOX share price.... The post Noxopharm Share Price Up on P...

The Noxopharm Ltd (ASX: NOX) share price gained more than 21% today, surging in a last-minute buying frenzy to close at 83 cents. Noxopharm is an Australian clinical-stage drug development company. Its Veyonda drug is being designed to sup...

Noxopharm (ASX:NOX) has announced the publication in an abstract form of the latest survival data from the LuPIN study ahead of a formal presentation to the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposiu...

ShareCafeHidden Gems Webinar Recap – NOX, VMS, EMU, RXL Catch up on the full webinar with presentations from Noxopharrm (ASX:NOX), Venture Minerals (ASX:VMS), EMU Resources (ASX:EMU) & Rox Resources (ASX:RXL) Hidden Gems Webinar Recap...

ShareCafeNoxopharm (ASX:NOX) – Hidden Gems Webinar Presentation     Presenter – Dr. Graham Kelly Founder & CEO  – Noxopharm Limited is a clinical-stage drug development company that focuses on the research and development of drugs to e...

The Noxopharm Ltd (ASX:NOX) share price launched up more than 7% today as the company released its report for the fourth quarter December 2020. At the time of writing, the Noxopharm share price trading up 7.69% at 63 cents. Let’s take a cl...

Noxopharm (ASX:NOX) has announced that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth and final dosage cohort.

A trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company's investors. Shares in the Sydney-based company were up nearly 3 per cent this morning...

A trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company's investors. Shares in the Sydney-based company were up nearly 3 per cent this morning...

A trial of medtech Noxopharm's (ASX: NOX) COVID-19 treatment has advanced to the fifth and final stage today, encouraging optimism amongst the company's investors. Shares in the Sydney-based company were up nearly 3 per cent this morning...

13 Jan 2021 - Drug development company, Noxopharm (ASX:NOX) reports that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth…

Noxopharm CEO Dr Graham Kelly speaks at the Switzer Small and Micro Cap Virtual Investor Day 2020.

While the S&P/ASX 200 Index (ASX: XJO) is slipping today, the Australian clinical-stage drug developer Noxopharm Ltd (ASX: NOX) is bucking the trend with its shares rising. At the time of writing, the Noxopharm share price is up 14.13%...

ShareCafeAustralia…One Hour In…ASX up 52 points ASX200 up 52 points (0.8%) to 6685.   Afterpay (+1.5%); Reserve Bank governor Philip Lowe said the bank was “unlikely” to conclude that Afterpay and other BNPL firms would have to remove thei...

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has completed a $23 million share placement to professional, institutional, and sophisticated investors.

ASX-listed drug developer is Noxopharm has put a $20 million equity raising to investors in an effort to fund studies slated for next year. 

Australian drug development company Noxopharm Limited (ASX: NOX) has announced a major breakthrough this morning on its DARRT cancer therapy drug.  The announcement shot the share price of NOX up by 11% to 63 cents at the opening bell. Wha...

Noxopharm (ASX:NOX) has announced its investigative cancer therapy Veyonda will be trialed with Bristol-Myers Squibb's immunotherapy OPDIVO (nivolumab).